Join
Live feed
·
PRReleasevia Quantisnow
Seelos Therapeutics Inc. logo

Seelos Therapeutics Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease

ByQuantisnow·Wall Street's wire, on your screen.
SEEL· Seelos Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SEEL (Seelos Therapeutics Inc.) and more on Quantisnow.